Medaysis
Enable Innovation

DATA SHEET

Rabbit Anti-HLA-ABC (MHC I) [MD330R]: RM0451, RM0451RTU7

Intended Use: For Research Use Only

Description: Reacts with a monomorphic determinant of human major histocompatibility (MHC) class I antigens (HLA-A, B and C). Human MHC class I antigens are expressed constitutively on all nucleated cells lymphocytes such as lymphocytes, thymocytes, granulocytes, and bone marrow cells and are absent on erythrocytes. MHC class I antigens play a role in class I MHC-associated antigen presentation, inhibition of NK cell cytotoxicity, tumor surveillance, and tissue allotransplantation.

Specifications:

Clone:	MD330R
Source:	Rabbit
Isotype:	IgG
Reactivity:	Human
Immunogen:	Recombinant fragment aa100-300 of human HLA class I protein
Localization:	Membrane
Formulation:	Purified antibody in PBS pH7.4, containing BSA and ≤ 0.09% sodium azide (NaN3)
Storage:	Store at 2°- 8°C
Applications:	IHC

Package:

Description	Catalog No.	Size
HLA-ABC (MHC I) Concentrated	RM0451	1 ml
HLA-ABC (MHC I) Prediluted	RM0451RTU7	7 ml

IHC Procedure*:

Positive Control Tissue:	Colonic carcinoma, stomach, liver, tonsil, lymph node
Concentrated Dilution:	25-200
Pretreatment:	Tris EDTA pH9.0, 15 minutes Pressure Cooker or 30-60 minutes water bath at 95°-99°C
Incubation Time and Temp:	30-60 minutes @ RT
Detection:	Refer to the detection system manual

* Result should be confirmed by an established diagnostic procedure.



FFPE human tonsil stained with anti-HLA-ABC using DAB

References:

1. Composition and Clinical Impact of the Immunologic Tumor Microenvironment in Oral Squamous Cell Carcinoma. Boxberg M, et al. J Immunol 202:278-291, 2019.
2. Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer. Watanabe S, et al. Cancer Sci 110:52-60, 2019.
3. Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens. Wedekind MF, et al. Pediatr Blood Cancer 65:e27313, 2018.

Orders: customercare@medaysis.com Support: techsupport@medaysis.com Tel: 877-524-9167 www.medaysis.com